SHAREHOLDER ALERT: GOSS R SRNE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / June 1, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Gossamer Bio, Inc. (NASDAQ:GOSS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/gossamer-bio-inc-loss-submission-form?prid=7058&wire=1
Lead Plaintiff Deadline: June 2, 2020
The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, 2019 initial public offering.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Ryder System, Inc. (NYSE:R)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ryder-system-inc-loss-submission-form?prid=7058&wire=1
Lead Plaintiff Deadline: July 20, 2020
Class Period: July 23, 2015 – February 13, 2020

Allegations against R include that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?prid=7058&wire=1
Lead Plaintiff Deadline: July 27, 2020
Class Period: May 15, 2020 – May 20, 2020

Allegations against SRNE include that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 592315